02:00 Wed 09 Sep 2020
Directa Plus PLC - Publication of Scientific Paper

("Directa Plus" or the "Company")
Publication of Scientific Paper from
Directa Plus (AIM: DCTA), a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets, is pleased to announce the publication in this month's
The project (GRATA - GRAfene per il Tessile Avanzato e la moda) was undertaken by the Materials for
The project group from Milan Polytechnic,
· G+® GNPs comply with ISO/TS 80004-13:2017 "graphene nanoplatelets" definition following an analysis of their morphology which showed a typical thickness below 3 nm and a lateral dimension of 3 µm;
· a very high crystalline quality of the GNPs, crucial for applications where thermal and electrical conductivity is targeted; and,
· G+® GNPs confer very high in-plane thermal conductivity to functional membranes, endorsing their use for thermal comfort.
The full scientific paper is available at https://onlinelibrary.wiley.com/doi/abs/10.1002/app.49645
Professor
For further information please visit http://www.directa-plus.com/ or contact:
| +39 02 36714458 |
|
|
|
|
|
|
Cenkos Securities plc (Nominated Adviser and Joint Broker) | +44 131 220 6939 |
|
|
|
|
N+1 Singer (Joint Broker) | +44 20 7496 3069 |
|
|
|
|
Tavistock (Financial PR and IR) | +44 20 7920 3150 |
|
|
About Directa Plus
Our focus is principally on the two sectors in which we have strong commercial advantage through developed and launched products and a technological lead: environmental (based on our Grafysorber® product) and textiles (based on our G+ products). In addition, we will continue to pursue opportunities in elastomers and composites (including tyres and asphalt), also using our G+ products. All our products are hypoallergenic, non-toxic and sustainably produced.
-ends-
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
FOR OUR FULL DISCLAIMER CLICK HERE